Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 991-998

  Labussière, Marianne ^a   Aarnink, Alice ^a   Pinel, Sophie ^a   Taillandier, Luc ^a,f   Escanyé, Jean Marie ^a   Barberi Heyob, Muriel ^b   Bernier Chastagner, Valérie ^c   Plénat, François ^a,d   Chastagner, Pascal ^a,e  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d CHU NANCY BRABOIS   (France)

^e HÔPITAL D ENFANTS   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Concomitant chemoradiotherapy; Liposomal doxorubicin; Malignant glioma

Indexed keywords

DOXORUBICIN; LIPOSOME; MACROGOL; PEGYLATED LIPOSOME; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENCAPSULATION; FEMALE; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRACRANIAL TUMOR; LIFE EXPECTANCY; MOUSE; NEWBORN; NONHUMAN; NUDE MOUSE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SUBCUTANEOUS TISSUE TUMOR; THERAPY EFFECT; TUMOR LOCALIZATION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; DOXORUBICIN; FEMALE; GLIOMA; HUMANS; MICE; RADIATION-SENSITIZING AGENTS; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54249166344     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328313e172     Document Type: Article

References (37)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109:93-108.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
3. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 1999; 125:481-486.
4. Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, et al. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int J Cancer 1994; 58:860-864.
5. Takamiya Y, Abe Y, Tanaka Y, Tsugu A, Kazuno M, Oshika Y, et al. Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts. Br J Cancer 1997; 76:445-450.
6. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54:1-7.
7. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety 2001; 24:903-920.
8. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51:691-743.
9. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454.
10. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36.
11. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 1997; 280:1406-1414.
12. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 1997; 280:1319-1327.
13. Unezaki S MK, Ishida O. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphopatic polyethylene glycol. Int J Pharm 1995; 126:41-48.
14. Arnold RD, Mager DE, Slack JE, Straubinger RM. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res 2005; 11:8856-8865.
15. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995; 83:1029-1037.
16. Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 1997; 14:992-998.
17. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001; 92:1936-1942.
18. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004; 100:1199-1207.
19. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - rationale for combination with radiotherapy. Acta Oncol 2000; 39:207-211.
20. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol 1990; 57:55-64.
21. Davies Cde L, Lundstrom LM, Frengen J, Eikenes L, Bruland SO, Kaalhus O, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 2004; 64:547-553.
22. Harrington KJ, Lewanski CR, Stewart JS. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development. Clin Oncol (R Coll Radiol) 2000; 12:2-15.
23. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007; 18:1159-1164.
24. Chastagner P, Kozin SV, Taghian A. Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiform xenografts in nude mice. Int J Radiat Oncol Biol Phys 2001; 50:777-782.
25. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003; 52:131-138.
26. Chastagner P, Labussiere M, Aarnink A, Pinel S, Bernier V, Plénat F, et al. Comparison of doxorubicin and a liposomal form as radiosensitizer in high grade glioma and rhabdomyosarcoma xenografts. Int J Radiat Oncol Biol Phys 2006; 66 (Suppl 1):S579.
27. Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S, et al. [Standards, options and recommendations 2002 for the management of adult patients with intracranial gliomas (summary report)]. Bull Cancer 2003; 90:873-886.
28. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, et al. Doxorubicin-loaded Fab′ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003; 63:86-92,
29. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42:419-436.
30. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000; 83:1281-1286.
31. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, et al. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 2000; 6:4939-4949.
32. Chastagner P, Bouffet E, Grill J, Kalifa C. What have we learnt from previous phase II trials to help in the management of childhood brain tumours? Eur J Cancer 2001; 37:1981-1993.
33. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology 1997; 48:1336-1340.
34. Gupta B, Torchilin VP. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 2007; 56:1215-1223.
35. Boucher Y, Salehi H, Witwer B, Harsh GRT, Jain RK. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 1997; 75:829-836.
36. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-622.
37. Charrois GJ, Allen TM. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003; 306:1058-1067.